EDESA BIOTECH, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
EDESA BIOTECH, INC. (EDSA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $502.68 per share for the 3-month period ending 2021-12-31, per its 10-Q filed 2022-02-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2022-12-16
- EDESA BIOTECH, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2014-12-31 was 0.25 CAD/shares.
- EDESA BIOTECH, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2015 was 3.06 CAD/shares, a 25.37% decline from fiscal 2014.
- EDESA BIOTECH, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2014 was 4.10 CAD/shares.
CAD/shares
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 1 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 1 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2015-09-30 | 3.06 CAD/shares 10-K · filed 2015-12-14 | ||||||
| 2015-06-30 | 0.25 CAD/shares 10-Q · filed 2015-08-10 | ||||||
| 2015-03-31 | 0.25 CAD/shares 10-Q · filed 2015-05-11 | ||||||
| 2014-12-31 | 0.25 CAD/shares 10-Q · filed 2015-02-09 | ||||||
| 2014-09-30 | 2.50 CAD/shares 10-K · filed 2015-12-14 | 0.25 CAD/shares 10-Q · filed 2015-02-09 | |||||
| 2014-08-31 | 4.10 CAD/shares 10-K · filed 2015-12-14 | 0.41 CAD/shares 10-Q · filed 2015-02-09 |
USD/shares
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2021-12-31 | $502.68 10-Q · filed 2022-02-14 | |||
| 2021-09-30 | $2.10 10-K · filed 2022-12-16 | |||
| 2021-06-30 | $2.12 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | $2.44 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | $0.00 10-Q · filed 2021-02-16 | |||
| 2020-09-30 | $2.60 10-K · filed 2021-12-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |